Cancer Liquid Biopsy Monitoring Study
Liquid biopsy is a test done on a sample of blood to examine pieces of DNA from tumor cells circulating in the blood (circulating tumor DNA, ctDNA). The detection of ctDNA in blood may be used to monitor treatment response, disease recurrence, and therapy resistance.
This study seeks to provide evidence that liquid biopsy monitoring provides useful genomic information for oncologists to improve how they treat their patients. Researchers at Sutter Health are collecting serial blood samples from eligible patients with newly diagnosed metastatic melanoma or metastatic lung cancer to monitor ctDNA mutations as participants undergo treatment. All participants will have results from ctDNA testing provided to their treating physicians.
Sub-Investigator
Mohammed Kashani-Sabet, M.D.Research topics
Related studies
View all studies- Research study
Bone Marrow Transplant Database
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
- Research study
Adjuvant Advanced Cervical Cancer GY037
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
- Research study
Ductal Carcinoma In Situ (DCIS) Registry Dana Farber
Molecular Characterization of Breast Cancer with Duct Forming Features
- Research study
Melanoma DECIDE
DecisionDx-Melanoma Impact in Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes
- Research study
Melanoma Follow Up R3767-ONC-2466
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613




